PDCD1 and neoplasm: IBI318/LY3434172 is an IgG-like dual antibody targeting PD-L1 and PD-1, and preclinical data suggest that it has significant tumor-suppressive effects and is superior to equivalent doses of monoclonal antibodies, as well as the combination of PD-1 and PD-L1 monoclonal antibodies (128).